athens - ene.gr · athens winter school in nephrology 27-29/2/2020 | 1 dear colleagues, it is a...

Div an i Pa l ace Ac ro po l i s Ho t e l

ATHENSGREECE

H e l l e n i c S o c i e t y o f N e p h r o l o g y

GLOMERULAR DISEASESF O C U S I N

27-29/2/2020

Winter Schoolin Nephrology

ATHENS

program

GRCY-GRC-P-416-0918-067614

Παρουσιάζονταςτο πρώτο και µοναδικόενδοφλέβιο ασβεστιοµιµητικό

®

AMGEN Hellas Ε.Π.Ε.Γραβιάς 4, 151 25 Μαρούσι

Τηλ: 210 3447000 - Fax: 210 3447050 Email: [email protected], www.amgen.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα

συμπληρώνοντας την “ΚΙΤΡΙΝΗ ΚΑΡΤΑ”

Αναφέρετε κάθε ύποπτη ανεπιθύμητη ενέργεια σύμφωνα με το εθνικό σύστημα αναφο-ράς στο Τμήμα Ανεπιθύμητων Ενεργειών του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ) Τηλ. 2132040380, Fax 2106549585, με τη χρήση της Κίτρινης Κάρτας διαθέσιμη και στην ιστοσελίδα του ΕΟΦ: www.eof.gr για έντυπη ή ηλεκτρονική υποβολή ή εναλλακτικά στην AMGEN Ελλάς Φαρμακευτικά Ε.Π.Ε. Τηλ.: +30 2103447000.

ATHENS WINTER SCHOOL IN NEPHROLOGY 27-29/2/2020 | 1

Dear colleagues,

It is a great pleasure and honor to welcome you in Athens be-

tween 27th and 29th of February 2020 in the joined meeting

organized by the Immunonephrology Working Group (IWG) of

ERA EDTA and Mayo Clinic (Rochester USA) in collaboration

with Hellenic Society of Nephrology. This meeting represents

a Winter School in Nephrology similar to the successful meet-

ing organized last year in Prague with the collaboration of

Professor Fernando Fervenza from Mayo Clinic and the

Board of IWG. According to the experience from last year, the

topics of presentation are selected by the speakers and are

not exclusively related to glomerular diseases. However,

glomerular diseases still represent the main topic of this Win-

ter School in Nephrology. New knowledge in pathogenesis

and new trends in the treatment of glomerular and other kid-

ney diseases including renal transplantation will be discussed

by distinct speakers with great experience in each topic.

We are anticipating you with great impatience and pleasure

for the Winter School of Nephrology 2020 in Athens, one of

the most attractive destinations in Europe.

Dimitrios S. Goumenos

Professor of Internal Medicine-Nephrology

Head of the School of Medicine of University of Patras

We

lc

om

e

le

tte

r

2 | ATHENS WINTER SCHOOL IN NEPHROLOGY 27-29/2/2020

ge

ne

ra

l i

nf

or

ma

to

n

Date and Venue

27 – 29 February 2020

Divani Palace Acropolis Hotel

Parthenonos 19, Athens

Tel: +30 210 9280100

Web site: www.divaniacropolishotel.com

Language

English is the official language of the Congress. Translation will not be

available

CME Accreditation

The Congress has been accredited by the Continuing Medical Educa-

tion from the Hellenic Medical Association with 19 CME credits

(ECMEC®s).

Congress Organizers

HELLENIC SOCIETY OF NEPHROLOGY

15 Meandrou Str. Athens, 11528 Greece

Τel: +30 210 7298586

Fax: +30 210 7237705

[email protected]

www.ene.gr

Congress Secretariat

C.T.M International S.A.

131, Vas. Sofias Av.

115 21 – Athens, Greece

Tel: +30 210 3244932

Fax: +30 210 3250660

www.ctmi.gr

pr

og

ra

m


Thursday 27 February, 2020 Hall Erechthion

16:00-16:45 Registration

16:45-17:00 Opening of the meeting

17:00-18:30 Registries on glomerular diseases

Chairpersons: Theophanis Apostolou, Marten Segelmark

Biopsy registries

Marten Segelmark

IgA nephropathy: Data from the Registry of Hellenic

Society of Nephrology

Marios Papasotiriou

Membranous nephropathy: Data from the Registry of

Hellenic Society of Nephrology

Maria Stangou

18:30-19:00 Focal segmental glomerulosclerosis

Chairpersons: Dimitrios Goumenos, Vasilios Liakopoulos

Differentiating primary, genetic and secondary FSGS

Fernando Fervenza

19:00-19:15 Co f f e e b r e a k

19:15-20:45 IgA nephropathy

Chairpersons: Dimitrios Goumenos, Rosanna Coppo

A detective control of complement regulation

in IgA nephropathy

Rosana Coppo

Novel treatment for IgA nephropathy: the case for

complement inhibition

Annette Bruchfeld

How to assess the risk of progression of IgA nephropathy

Rosana Coppo


pr

og

ra

m

Friday 28 February, 2020 Hall Erechthion

8:30-9:30 C3, Interstitial nephritis

Chairpersons: Evangelos Papachristou, Gema Fernandez

Update on C3 glomerulopathy

Kultigin Turkmen

Treatment of acute tubulointerstitial nephritis

Gema Fernandez

9:30-11:00 Membranous nephropathy /

Monoclonal gammopathies

Chairpersons: Aikaterini Papagianni, Fernando Fervenza

New antigens in membranous nephropathy

Sanjeev Sethi

Monoclonal gammopathy-associated renal diseases

Sanjeev Sethi

Membranous nephropathy – what have we learned from

MENTOR?

Fernando Fervenza

11:00-11:15 Co f f e e b r e a k

11:15-12:45 Vasculitides

Chairpersons: Ploumis Passadakis, Rodrigo Cartin-Ceba

Differences in epidemiology, prognosis and treatment

of ANCA associated vasculitis

Rodrigo Cartin-Ceba

Kidney involvement in ANCA associated vasculitis

Sophia Lionaki

The role of complement in ANCA Associated Vasculitis (AAV)

Vladimir Tesar

pr

og

ra

m


Friday 28 February, 2020 Hall Erechthion

12:45-13:45 Thrombotic microangiopathies / hemodialysis

Chairpersons: Stylianos Panagoutsos, Kultigin Turkmen

Atypical Hemolytic Uremic Syndrome (aHUS)

Vladimir Tesar

Infectious complications of dialysis

An De Vriese

13:45-15:45 B r e a k

15:45-17:15 Other glomerular diseases

Chairpersons: Elias Thodis, Dario Roccatello

An update on Anti-GBM disease

Marten Segelmark

HCV-associated glomerulonephritis/vasculitis: current

treatment considerations in the era of direct antiviral drugs

Annette Bruchfeld

Treatment of cryoglobulinemic nephritis

Dario Roccatello

17:15-18:45 Kidney transplantation

Chairpersons: Ioannis N. Boletis, Annette Bruchfeld

Practical guide to interpreting donor specific antibody

testing in the current era

Carrie Schinstock

Making sense of the varied presentations of antibody

mediated rejection in the renal allograft

Carrie Schinstock

Ischemia and reperfusion injury in transplantation

Cees van Kooten


pr

og

ra

m

Saturday 29 February, 2020 Hall Erechthion

8:30-10:30 Polycystic kidney disease

Chairpersons: Eugenios Dafnis, Fouad Chebib

Prognostication in ADPKD

Fouad Chebib

Clinical implications of genetic testing in ADPKD patients

Emile Cornec Le Gall

The role of genetic modifiers and molecular interactions

in ARPKD diagnosis and prognosis

Paraskevi Goggolidou

Advances in management of patients with ADPKD

Fouad Chebib

10:30-10:45 Co f f e e b r e a k

10:45-12:15 Lupus nephritis

Chairpersons: Ioannis N. Boletis, Vladimir Tesar

New insights in the pathogenesis of lupus nephritis

Eleni Frangou

New treatment strategies in lupus nephritis

Ladan Zand

New avenues in lupus nephritis (clinical lecture)

Hans Joachim Anders

pr

og

ra

m



12:15-13:45 Monoclonal gammopathie /

Membranous nephropathy

Chairpersons: Dimitrios Vlachakos, Ladan Zand

Reappraisal of AntiPLA2R antibodies in serum and

kidney tissue of patients with membranous nephropathy

Dimitrios Goumenos

Cast nephropathy

Vladimir Tesar

Monoclonal gammopathy of renal significance: when

to do renal biopsy and how to treat?

Ladan Zand

13:45-16:00 B r e a k

16:00-17:15 Chronic kidney disease

Chairpersons: Ioannis Stefanidis, Antonello Pani

Prevalence of CKD and its relationship to eGFR-related

genetic loci and clinical risk factors in a general

population (the SardiNIA study cohort)

Antonello Pani

The role of hypertension, proteinuria and dietary protein

consumption in the progression of kidney disease

Pantelis Sarafidis

Kidney size in relation to ageing, gender, renal function,

birthweight and chronic kidney disease risk factors in

a general population (Aging Kidney)

Antonello Pani

17:15-17:30 Co f f e e b r e a k

pr

og

ra

m



17:30-19:00 Pregnancy and kidney

Chairpersons: Aikaterini Papagianni, Andrea Kattah

Preeclampsia: Update on pathogenesis and

long-term implications

Andrea Kattah

Pregnancy in women with glomerulonephritis

Smaragdi Marinaki

Effects of pregnancy on the transplanted kidney

Andrea Kattah

19:00-20:00 Perspectives for novel therapies

Chairpersons: Ploumis Passadakis,

Hans Joachim Anders

Targeting podocytes beyond standard-of-care

Hans Joachim Anders

Antifibrotic therapies: where and why in human

kidney disease

Dimitrios Goumenos

sp

ea

ke

rs

- c

ha

irp

er

so

ns


Anders Hans Joachim, Professor Dr Nephrology Center Department of Inter-

nal Medicine IV Department of LMU Munich, Germany

Apostolou Theofanis, MD, PhD Director of Nephrology Department “Antonios

G Billis” Evangelismos General Hospital, Athens. President of Hellenic Society

of Nephrology, Greece

Boletis N. Ioannis, Professor of Internal Medicine-Nephrology, Medical

School, National and Kapodistrian University of Athens, Director of Nephrology

Department and Renal Transplantation, Unit, Laiko, General Hospital, Athens,

Greece

Bruchfeld Annette, Professor of Nephrology, Karolinska University Hospital

and Karolinska Institutet, Stockholm, Sweden

Cartin-Ceba Rodrigo, MD, MSc Associate Professor of Medicine Consultant,

Pulmonary and Critical Care Medicine Mayo Clinic Arizona, USA

Chebib Fouad, MD, FASN, Assistant Professor of Medicine, Mayo College of

Medicine, Senior Associate Consultant, Division of Nephrology and Hyperten-

sion, Mayo Clinic, Rochester, USA

Coppo Rosana, MD, Fondazione Ricerca Molinette, Regina Margherita Hos-

pital, Turin, Italy

Cornec Le Gall Emile, MD, PhD,Associate Professor Division of Nephrology

University Hospital,Genetics Genomics and Biotechnologies, Brest, France

Dafnis Eugenios, Associate Professor of Nephrololy University of Crete, Chief

of Nephrology Division University Hospital of Iraklion, Greece

De Vriese An, MD, PhD, Head of the Renal Unit, AZ Sint-Jan Brugge, and

Guest Professor Ghent University, Belgium

Fernandez Gema, Hospital Universitario Fundacion Alcorcon, Departamento

de Nefrología, Madrid, Spain

Fervenza C. Fernando, MD, PhD, Professor of Medicine, Mayo Clinic School

of Medicine, USA

Frangou Eleni, MD, PhD Nephrologist, Limassol General Hospital, Limassol,

Cyprus, Biomedical Research Foundation of the Academy of Athens, Athens,

Greece

Goggolidou Paraskevi, BSc Hons, DPhil (Oxon), FHEA, FIBMS, Reader in

Molecular Genetics, University of Wolverhampton, UK

sp

ea

ke

rs

- c

ha

irp

er

so

ns


Goumenos S. Dimitrios, Professor of Nephrology, Director of Nephrology and

Renal Transplantation Department, Patras University Hospital, Head of

Medicine University of Patras, Greece

Kattah Andrea, MD is Nephrologist in Rochester, Minnesota. She is affiliated

with Mayo Clinic Hospital - Rochester, USA

Liakopoulos Vasilios, Associate Professor of Nephrology,Division of Nephrol-

ogy and Hypertension 1st Department of Internal Medicine AHEPA Hospital

School of Medicine Aristotle University of Thessaloniki, Greece

Lionaki Sophia, MD, Consultant Nephrologist, Department of Nephrology &

Transplantation, Laiko Hospital, National & Kapodistrian University of Athens,

Faculty of Medicine, Greece

Marinaki Smaragdi, Assistant Professor of Nephrology Medical School, Uni-

versity of Athens Nephrology Department and Renal Transplant Unit, Laiko

General Hospital, Athens, Greece

Panagoutsos Stylianos, Professor of Nephrology Democritus University of

Thrace University General Hospital of Alexandroupolis, Greece

Pani Antonello, Director Nephrology and Dialysis Unit, Associate Professor

of Nephrology, Director of Department Kidney Diseases and Transplantation,

Italy

Papachristou Evangelos, Associate Professor of Internal Medicine - Nephrol-

ogy Department of Nephrology School of Medicine University of Patras,

Greece

Papagianni Aikaterini, Professor of Nephrology, Aristotle University of Thes-

saloniki, Director, Department of Nephrology, General Hospital “Hippokratio”,

Thessaloniki, Greece

Papasotiriou Marios, Associate Professor of Internal Medicine-Nephrology,

Nephrology Department, University Hospital of Patras, Greece

Passadakis S. Ploumis, MD, Dean of Faculty of Health Sciences, Democritus

University of Thrace, Professor of Nephrology, Division of Nephrology, Univer-

sity Hospital of Alexandroupolis, Greece

Roccatello Dario, Professor of Nephrology, Treatment of cryoglobulinemic

nephritis, University of Turin, Italy

sp

ea

ke

rs

- c

ha

irp

er

so

ns


Sarafidis Pantelis, Associate Professor in Nephrology, Department of

Nephrology, Hippokration Hospital,Aristotle University of Thessaloniki, Greece

Schinstock A. Carrie, MD, Associate Professor of Medicine, Division of

Nephrology and Hypertension, William J von Liebig Center for Transplantation

and Clinical Regeneration, Rochester, USA

Segelmark Mårten, Professor of Nephrology, Lund University, Sweden

Sethi Sanjeev, MD, Professor of Laboratory Medicine and Pathology, Mayo

Clinic, USA

Stangou Maria, MD, PhD, Assistant Professor of Nephrology Aristotle Univer-

sity of Thessaloniki, Department of Nephrology Hippokration Hospital, Thes-

saloniki, Greece

Stefanidis Ioannis, MD, PhD, Professor of Internal Medicine/Nephrology,

Dean of the Faculty of Medicine School of Health Sciences, University of Thes-

saly, Larissa, Greece

Tesar Vladimir, Professor MD, PhD, MBA, FERA, FASN, Czech Republic

Thodis Elias, Professor of Nephrology Medical School Democritus University

of Thrace, Greece

Turkmen Kultigin, MD, Professor, Necmettin Erbakan University Meram

School of Medicine, Department of Internal Medicine Division of Nephrology

Konya, Turkey

van Kooten Cees, Professor Dr, PhD, Professor in Experimental Nephrology

and Transplant Immunology, at the Department of Internal Medicine-Nephrol-

ogy, Leiden University Medical Center, Leiden, The Netherlands

Vlachakos Dimitrios, MD, PhD, Professor of Medicine and Nephrology, Na-

tional and Kapodistrian University of Athens Medical School, Greece

Zand Ladan, MD, Associate Professor at University of Minnesota, affiliated

with Mayo Clinic, USA

sp

on

so

rs


The Organizing Committee wishes to thank

the below-mentioned Companies:

GRCY

-GRC-P-291N

NE-0918-067565

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα

συμπληρώνοντας την “ΚΙΤΡΙΝΗ ΚΑΡΤΑ”

Αναφέρετε κάθε ύποπτη ανεπιθύμητη ενέργεια σύμφωνα με το εθνικό σύστημα αναφοράς στο Τμήμα Ανεπιθύμητων Ενεργειών του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ) Τηλ. 2132040380, Fax 2106549585, με τη χρήση της Κίτρινης Κάρτας διαθέσιμη και στην ιστοσελίδα του ΕΟΦ: www.eof.gr για έντυπη ή ηλεκτρονική υποβολή ή εναλλακτικά στην AMGEN Ελλάς Φαρμακευτικά Ε.Π.Ε. Τηλ.: +30 2103447000.

Περαιτέρω πληροφορίες διατίθενται από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως ή περιλαμβάνονται στην συνοπτική περιγραφή χαρακτηριστικών του προϊόντος, το φύλλο οδηγιών χρήσης και τη μονογραφία του φαρμάκου.

Sevelamer CarbonateEπικαλυμμένα με λεπτό υμένιο δισκία

Για περισσότερες πληροφορίες, απευθυνθείτε στην εταιρεία:Mediprime S.A.Διονύσου 136, 151 24 Μαρούσι, ΑθήναT 210 283 7640 www.mediprime.gr

A-0

1527

athens - ene.gr · athens winter school in nephrology 27-29/2/2020 | 1 dear colleagues, it is a...

Documents